AN2 Therapeutics (ANTX) Director Readnour Sells 35,402 Shares

What Happened

• Robin Shane Readnour, a member of AN2 Therapeutics' board (reported in connection with interests held by MGC Venture Partners entities), sold a total of 35,402 shares of AN2 common stock in two transactions on August 17, 2026. The filings report sales of 16,696 shares for $100,313 and 18,706 shares for $112,389, for an aggregate proceeds of $212,702. The reported weighted-average price across the sales was $6.01 (individual sale prices ranged from $6.00 to $6.07).

Key Details

• Transaction date: August 17, 2026; Form 4 filed August 19, 2026 (filed within the typical 2-business-day window).
• Shares sold: 16,696 and 18,706 (total 35,402).
• Prices/values: weighted average $6.01; proceeds $100,313 and $112,389 (total ~$212,702). Price range $6.00–$6.07 (reporting person can provide per-price breakdown on request).
• Who sold: sales were executed by MGC Venture Partners 2018, LP and MGC Venture Partners QP 2018, LP. Readnour is a managing partner/member of the related GP/LP entities and disclaims direct beneficial ownership except to the extent of any pecuniary interest.
• Mechanism: Sales occurred automatically under Rule 10b5-1 trading plans adopted April 23, 2026 (automatic plan sales — typically pre-set and not timed to inside information).
• Shares owned after transaction: not specified in the excerpt of the filing provided.

Context

• These were sales, not purchases. Sales made under 10b5-1 plans are generally pre-arranged and routine; they do not necessarily indicate the insider’s current view of the company’s prospects. The trades appear to be institutional holdings managed through MGC Venture Partners entities rather than a direct, personal open-market sale by the director.